Ascentage Pharma reports positive pipeline data ahead of ASCO showcase
Ascentage Pharma (NASDAQ:AAPG) announced that abstracts for six of its clinical studies have been published ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, outlining early-phase therapeutic activity across its core pipeline of targeted oncology candidates.
The clinical readouts span six upcoming presentations—including three selected for rapid oral slots and three designated as posters—evaluating the company’s primary pipeline assets: the BCR-ABL inhibitor olverembatinib, the Bcl-2 inhibitor lisaftoclax, and the MDM2-p53 inhibitor alrizomadlin.
The abstracts emphasize structural response rates across multi-line leukemias, pediatric sarcomas, and rare gastrointestinal tumors.
In data evaluating olverembatinib in combination with blinatumomab for aggressive Philadelphia chromosome-positive leukemias, four out of five patients presenting with minimal residual disease (MRD) positivity achieved a complete response, with two converting to full MRD negativity.
Parallel data evaluating olverembatinib monotherapy as a second-line treatment for chronic-phase chronic myeloid leukemia (CP-CML) showed that among 42 evaluable participants, 91.3% reached a complete cytogenetic response (CCyR) and 60.9% achieved a major molecular response (MMR) by the 24th treatment cycle.
For a distinct cohort of CP-CML patients who had previously failed second-generation tyrosine kinase inhibitors (TKIs), the compound induced an 81.3% CCyR and a 50% MMR rate.
The data also tracked combinations moving into solid tumor indications.
A pediatric combination trial pairing alrizomadlin with lisaftoclax generated a 30% objective response rate and an 80% disease control rate in pediatric patients with relapsed or metastatic rhabdomyosarcoma, logging no dose-limiting toxicities.
Separately, translational results for olverembatinib in succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) tracked a 23.1% partial response rate alongside a median progression-free survival of 25.7 months.
The reported outcomes remain constrained by early-phase limitations, as the high-percentage efficacy metrics were derived from single-arm or early exploratory cohorts with narrow patient sets.
Additionally, because the company’s pivotal global Phase 3 registrational studies—specifically the POLARIS-2 trial for olverembatinib and the GLORA study for lisaftoclax—are still actively enrolling, no definitive clinical outcome or survival data for these large-scale comparison arms have been disclosed.
None of the three evaluated drug candidates are currently approved by the U.S. Food and Drug Administration.